Peripheral T-Cell Lymphoma

This is a type of lymphoma that starts in T-cells found in the fluid outside of lymph nodes. It's a specific type of T-cell lymphoma that affects areas outside the lymph nodes.

Condition

What people with Peripheral T-Cell Lymphoma report

Every report comes from a Lived member, sent anonymously.

Have you had Chemotherapy infusion for Peripheral T-Cell Lymphoma?

NameHow it went

About Peripheral T-Cell Lymphoma

What It Is

Peripheral T-cell lymphoma (PTCL) is a group of uncommon non-Hodgkin lymphomas that start in mature T cells, a type of white blood cell that helps direct the immune system. The abnormal T cells multiply and collect in lymph nodes and can also involve the spleen, liver, bone marrow, skin or digestive tract. "Peripheral" does not refer to the hands or feet: it means the cancer arises from T cells that have already left the bone marrow and thymus where they develop. PTCL makes up roughly 1 in 10 non-Hodgkin lymphomas. PTCL is an umbrella term, and the specific subtype shapes treatment and outlook. The most common in the United States is PTCL not otherwise specified (PTCL-NOS), a label for T-cell lymphomas that do not fit another group. Others include angioimmunoblastic T-cell lymphoma (AITL), which often causes widespread lymph node swelling, fever, rash and immune problems, and anaplastic large cell lymphoma (ALCL). ALCL is divided by whether the cells carry a change in the ALK (anaplastic lymphoma kinase) gene; ALK-positive ALCL tends to affect younger people and responds better to treatment. Most types of PTCL are aggressive, meaning they grow over weeks to months and need treatment soon after diagnosis. Skin-based T-cell lymphomas, such as mycosis fungoides, are usually treated as a separate group.

Causes & Risk Factors

For most people with PTCL, no specific cause is found, and nothing they did is known to have brought it on. It is most often diagnosed in people in their 60s, although ALK-positive ALCL is more common in children and young adults. A few factors are linked to particular subtypes. Infection with human T-cell lymphotropic virus type 1 (HTLV-1), which is rare in the United States but more common in Japan, the Caribbean and parts of Africa, causes adult T-cell leukemia/lymphoma. The Epstein-Barr virus is associated with a type that affects the nose and throat, more common in Asia and South America. Long-standing celiac disease, particularly when diagnosed in adulthood, is linked to a T-cell lymphoma of the intestine, and textured breast implants are linked to a rare form of ALCL that develops in the scar tissue around the implant. More broadly, a weakened immune system, such as after an organ transplant, raises the risk of lymphoma. These links raise the odds; they do not mean a person with one of them will develop PTCL.

How It's Diagnosed

PTCL often first shows up as painless, enlarged lymph nodes in the neck, armpit or groin, sometimes with fever, drenching night sweats or unintended weight loss of 10% or more of body weight over six months. Because these symptoms are far more often caused by infections, a diagnosis always depends on a biopsy. Removing a whole lymph node, or a generous core of tissue, gives the pathologist enough material to see the cell pattern and run tests on the cells' surface markers and genes. T-cell lymphomas can be hard to classify, so review by a hematopathologist (a pathologist who specializes in blood cancers and lymphoma) is important. Tests for marker proteins such as CD30 and ALK help pin down the subtype and point to treatment options. Once lymphoma is confirmed, staging shows how far it has spread. This usually involves a PET-CT scan (imaging that shows where active lymphoma is throughout the body), blood tests including lactate dehydrogenase (LDH, an enzyme that rises when lymphoma is active), and sometimes a bone marrow biopsy. Before chemotherapy, people are generally tested for HIV and hepatitis B and C, since these infections affect how treatment is planned.

Treatment Options

PTCL is often treated with the goal of cure, and the first treatment matters most. For most subtypes, it is a combination of chemotherapy drugs given into a vein in repeated cycles. A common regimen is CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone), sometimes with etoposide added (CHOEP). When the lymphoma cells carry a surface protein called CD30, as ALCL does and some other subtypes can, brentuximab vedotin (Adcetris) can replace vincristine. It is an antibody that seeks out CD30 and delivers a cell-killing drug directly to the lymphoma. In a large trial, mostly of people with ALCL, this combination helped more people stay alive at five years than standard CHOP; the benefit for other subtypes is less certain. Numbness or tingling in the hands and feet from nerve damage is a common side effect that builds up with doses and is watched throughout treatment. Because PTCL often returns, some people in a first remission are offered high-dose chemotherapy followed by an autologous stem cell transplant, which uses their own previously collected blood-forming cells to recover. The evidence for this step comes from nonrandomized studies, and it is weighed against age, fitness and subtype. In specific cases, radiation is given after chemotherapy, although its value for limited-stage disease is debated. If the lymphoma comes back or does not respond, options include different chemotherapy combinations, brentuximab vedotin for CD30-positive disease, newer targeted drugs and clinical trials. A donor (allogeneic) stem cell transplant can control lymphoma that resists other treatment, but it carries a substantial risk of serious complications. A rare form of ALCL limited to the scar capsule around a breast implant can often be treated by removing the implant and capsule alone.

What to Expect

First treatment takes several months of repeated chemotherapy cycles, with blood tests and scans along the way to check the response. Chemotherapy lowers the white blood cell count, which makes infections more likely and more dangerous, so medicines to prevent certain infections are usually part of the plan. Fatigue and other side effects often mean adjusting work and daily commitments during this time. Outlook depends heavily on the subtype, the stage and a person's age and overall health. ALK-positive ALCL has the best results, with about 70% to 80% of people alive five years after diagnosis. For PTCL as a whole, older studies put five-year survival at about 30% to 40%, and AITL and PTCL-NOS tend to be harder to treat. These figures describe groups and predate some newer treatments, so a care team can give a more personal estimate. Many people respond well at first, but relapse is common, which is why follow-up visits and scans continue for years. Long-term effects of treatment can include reduced fertility, weakening of the heart muscle after doxorubicin, and a higher risk of other cancers later in life. These risks are worth raising before treatment starts, and they are one reason long-term follow-up continues after the lymphoma is gone.

When to Seek Help

See a clinician if an enlarged lymph node does not go away without an obvious infection to explain it, or if you have unexplained fevers, drenching night sweats or weight loss you cannot account for. During treatment, contact your care team right away for a fever of 100.5 F (38 C) or higher, shaking chills, or other signs of infection such as a new cough or redness around an IV line. Infections can become serious quickly when chemotherapy has lowered the white blood cell count, so follow the specific fever instructions your team gives you. Also report new numbness, tingling or weakness in the hands or feet, and any lump, fever or sweats that return after treatment ends.

Questions to Ask Your Doctor

  1. 1.Which subtype of PTCL do I have, and has the biopsy been reviewed by a lymphoma pathologist?
  2. 2.Is the lymphoma CD30-positive or ALK-positive, and how does that change my treatment?
  3. 3.Would a stem cell transplant or a clinical trial make sense for me now or later?
  4. 4.What side effects should I expect, and what should I do if I get a fever during treatment?
  5. 5.What should I do before treatment starts to protect my fertility or heart health?

Last reviewed • Oct 2026

Educational content, not medical advice.